Wall Street analysts expect that FibroGen Inc (NASDAQ:FGEN) will report ($0.39) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for FibroGen’s earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at $0.03. FibroGen posted earnings per share of $0.23 in the same quarter last year, which indicates a negative year over year growth rate of 269.6%. The company is expected to issue its next quarterly earnings results on Wednesday, February 26th.
On average, analysts expect that FibroGen will report full-year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.57) to $0.28. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($1.76) to $1.82. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover FibroGen.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The business had revenue of $33.17 million during the quarter, compared to analysts’ expectations of $31.61 million. During the same period in the prior year, the company earned ($0.50) earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis.
In other news, Director Kalevi Kurkijarvi sold 6,000 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $36.73, for a total value of $220,380.00. Following the completion of the sale, the director now directly owns 34,400 shares of the company’s stock, valued at $1,263,512. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Pat Cotroneo sold 3,201 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $41.38, for a total transaction of $132,457.38. Following the completion of the sale, the chief financial officer now directly owns 244,432 shares of the company’s stock, valued at $10,114,596.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,495 shares of company stock valued at $1,351,069. Corporate insiders own 7.83% of the company’s stock.
Large investors have recently modified their holdings of the stock. Captrust Financial Advisors bought a new position in shares of FibroGen during the second quarter worth $90,000. US Bancorp DE boosted its position in shares of FibroGen by 79.7% during the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 963 shares during the last quarter. Usca Ria LLC bought a new position in shares of FibroGen during the third quarter worth $123,000. Convergence Investment Partners LLC bought a new position in shares of FibroGen during the third quarter worth $137,000. Finally, Nisa Investment Advisors LLC boosted its position in shares of FibroGen by 729.8% during the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 3,430 shares during the last quarter. Hedge funds and other institutional investors own 68.71% of the company’s stock.
FGEN stock traded up $1.00 during midday trading on Friday, reaching $48.76. 25,137 shares of the company’s stock traded hands, compared to its average volume of 975,806. FibroGen has a 52-week low of $32.33 and a 52-week high of $61.23. The stock has a market cap of $4.13 billion, a P/E ratio of -47.35 and a beta of 1.84. The company has a current ratio of 9.01, a quick ratio of 8.95 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average is $40.28 and its 200 day moving average is $41.61.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.